Abstract

Chondrosarcomas are primary cancers of cartilaginous tissue with highly contrasting prognoses. These tumors are defined by recurrent mutations in the IDH genes and other genetic alterations including inactivation of CDKN2A and COL2A1; however, these have no clinical value. Here we use multi-omics molecular profiles from a series of cartilage tumors and find an mRNA classification that identifies two subtypes of chondrosarcomas defined by a balance in tumor differentiation and cell cycle activation. The microRNA classification reveals the importance of the loss of expression of the 14q32 locus in defining the level of malignancy. Finally, DNA methylation is associated with IDH mutations. We can use the multi-omics classifications to predict outcome. We propose an mRNA-only classifier to reproduce the integrated multi-omics classification, and its application to relapsed tumor samples shows the progressive nature of the classification. Thus, it may be possible to use mRNA-based signatures to detect patients with high-risk chondrosarcomas.

Details

Title
Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression
Author
Nicolle, Rémy 1   VIAFID ORCID Logo  ; Ayadi, Mira 1   VIAFID ORCID Logo  ; Gomez-Brouchet, Anne 2 ; Armenoult, Lucile 1 ; Banneau, Guillaume 1 ; Elarouci, Nabila 1 ; Tallegas, Matthias 3 ; Anne-Valérie Decouvelaere 4 ; Aubert, Sébastien 5 ; Rédini, Françoise 6 ; Marie, Béatrice 7 ; Labit-Bouvier, Corinne 8 ; Reina, Nicolas 9 ; Karanian, Marie 4 ; Louis-Romée le Nail 10 ; Anract, Philippe 11 ; Gouin, François 12 ; Larousserie, Frédérique 13 ; de Reyniès, Aurélien 1 ; de Pinieux, Gonzague 14 

 Programme Cartes d’Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France 
 Department of Pathology, CHU de Toulouse – Oncopole, Université de Toulouse, Toulouse, France 
 Plateforme de Génétique Moléculaire des Cancers, CHRU de Tours, Tours, France 
 Department of Biopathology, Centre Léon Bérard, Lyon, France; University of Lyon, Université Claude Bernard Lyon 1, CNRS 5286, INSERM U1052, Cancer Research Centre of Lyon, Lyon, France 
 Department of Pathology, CHU de Lille, Université de Lille, Lille, France 
 UMR1238 INSERM Université de Nantes, Sarcomes osseux et remodelage des tissus calcifiés, Faculté de médecine, NANTES, France 
 Department of Pathology, CHU de Nancy, Nancy, France 
 Department of Pathology, CHU de Marseille, Aix Marseille Université, INSERM, MMG, Marseille, France 
 Department of Orthopedic Surgery, Hôpital Pierre-Paul Riquet, CHU de Toulouse, Toulouse, France 
10  UMR1238 INSERM Université de Nantes, Sarcomes osseux et remodelage des tissus calcifiés, Faculté de médecine, NANTES, France; Department of Orthopedic Surgery, CHRU de Tours, Université de Tours, Tours, France 
11  Department of Orthopedic Surgery, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Sorbonne Paris Cité, Paris, France 
12  Department of Surgery, Centre Léon Bérard, Lyon, France; Department of Orthopaedic Surgery, CHU Nantes, Nantes, France 
13  Service de Pathologie, Hôpital Cochin, AP-HP, Université Paris Descartes, Paris, France 
14  UMR1238 INSERM Université de Nantes, Sarcomes osseux et remodelage des tissus calcifiés, Faculté de médecine, NANTES, France; Department of Pathology, CHRU de Tours, Université de Tours, Tours, France 
Pages
1-11
Publication year
2019
Publication date
Oct 2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2304105023
Copyright
© 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.